학술논문
Measuring and mapping the global burden of antimicrobial resistance
Document Type
Report
Author
Source
BMC Medicine. June 4, 2018, Vol. 16 Issue 1
Subject
Language
English
ISSN
1741-7015
Abstract
Author(s): Simon I. Hay[sup.1,2] , Puja C. Rao[sup.1] , Christiane Dolecek[sup.3,4] , Nicholas P. J. Day[sup.3,4] , Andy Stergachis[sup.5] , Alan D. Lopez[sup.2,6] and Christopher J. L. Murray[sup.1] Background Antimicrobial [...]
The increasing number and global distribution of pathogens resistant to antimicrobial drugs is potentially one of the greatest threats to global health, leading to health crises arising from infections that were once easy to treat. Infections resistant to antimicrobial treatment frequently result in longer hospital stays, higher medical costs, and increased mortality. Despite the long-standing recognition of antimicrobial resistance (AMR) across many settings, there is surprisingly poor information about its geographical distribution over time and trends in its population prevalence and incidence. This makes reliable assessments of the health burden attributable to AMR difficult, weakening the evidence base to drive forward research and policy agendas to combat AMR. The inclusion of mortality and morbidity data related to drug-resistant infections into the annual Global Burden of Disease Study should help fill this policy void. Keywords: Antimicrobial resistance, Drug-resistant infections, Microbial, Anti-infective agents, Antimicrobial drugs, Global health, Global burden of disease, Public health
The increasing number and global distribution of pathogens resistant to antimicrobial drugs is potentially one of the greatest threats to global health, leading to health crises arising from infections that were once easy to treat. Infections resistant to antimicrobial treatment frequently result in longer hospital stays, higher medical costs, and increased mortality. Despite the long-standing recognition of antimicrobial resistance (AMR) across many settings, there is surprisingly poor information about its geographical distribution over time and trends in its population prevalence and incidence. This makes reliable assessments of the health burden attributable to AMR difficult, weakening the evidence base to drive forward research and policy agendas to combat AMR. The inclusion of mortality and morbidity data related to drug-resistant infections into the annual Global Burden of Disease Study should help fill this policy void. Keywords: Antimicrobial resistance, Drug-resistant infections, Microbial, Anti-infective agents, Antimicrobial drugs, Global health, Global burden of disease, Public health